Open AccessRISKS ASSOCIATED WITH CONVERSION OF STABLE PATIENTS AFTER LIVER TRANSPLANTATION TO THE MICROEMULSION FORMULATION OF CYCLOSPORINE1
Author(s) -
Chris E. Freise,
Cynthia A. Galbraith,
B. Nikolai,
Nancy L. Ascher,
John R. Lake,
Peter Stock,
John P. Roberts
Publication year - 1998
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199804150-00022
Subject(s) - medicine , adverse effect , liver transplantation , transplantation , pharmacokinetics , biopsy , trough level , prospective cohort study , surgery , tacrolimus
Neoral is a microemulsion formulation of cyclosporine that has a better pharmacokinetic profile than the standard formulation (Sandimmune). To prove the safety of converting stable liver transplant patients from Sandimmune to Neoral, we conducted a prospective trial involving 54 patients.